Chromatin, Dow AgroSciences achieve first milestone in research collaboration

NewsGuard 100/100 Score

Chromatin Inc. announced today that they have reached the first milestone in their research collaboration with Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company. This collaboration is focused on developing a novel combination of Chromatin's Mini-Chromosomes with Dow AgroSciences' EXZACT™ Precision Technology.

“The achievement of this milestone sets our research program and collaboration on a path to long-term success. Together, Chromatin and Dow AgroSciences aim to bring this technology innovation to the market, which will deliver value for crop developers and growers alike”

Chromatin's Mini-Chromosomes are autonomous genetic elements built to deliver a complex of traits of importance to growers, processors and consumers - without impacting the native genome. Dow AgroSciences' EXZACT™ Precision Technology provides a versatile and comprehensive toolkit for targeted genome modification in plants and delivers a means for engineering multi-gene stacks, editing native genes and deleting undesirable traits.

The goal of the research program is to create a combined platform that allows for direct modification or updating of trait combinations, via EXZACT™, on a Mini-Chromosome inside a plant cell in real time, thereby avoiding the need to re-engineer a new Mini-Chromosome from the ground up. Such a platform would improve the flexibility and efficiency of the processes for creating and breeding new varieties carrying valuable traits. "The achievement of this milestone sets our research program and collaboration on a path to long-term success. Together, Chromatin and Dow AgroSciences aim to bring this technology innovation to the market, which will deliver value for crop developers and growers alike," said David Jessen, CTO of Chromatin.

Source:

Chromatin, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research sheds light on how GLP-1 obesity drugs may change food cravings